Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Angiogenesis inhibiting therapy in endocrine-resistant and triple negative breast cancer
2010-022065-10Phase 2Terminated
- Sponsor
- Sahlgrenska University Hospital
- Start
- Feb 2011
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of bevacizumab, capecitabine and cyclophosphamide in breast cancer and triple-negative breast cancer (TNBC) (2 cohorts), sponsored by Sahlgrenska University Hospital. Primary endpoint: Overall response rate. Started Feb 2011; status: terminated.
02
Drugs
bevacizumabcapecitabinecyclophosphamide
03
Conditions
breast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2010-022065-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022065-10.